Product Information
CHOLESTYRAMINE PACKET is a generic product labeled by Ascend Laboratories, LLC, priced at $0.8343 per EA under NDC 67877029860. Its NADAC has been published 238 times since Dec 22, 2021.
FDA first approved this application on Oct 19, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
4 g/8.78g
Manufacturer
Ascend Laboratories, LLCNDC
67877029860
Classification
Generic
Dosage Form
POWDER, FOR SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CHOLESTYRAMINEApproval Type
Generic (ANDA)
FDA Application
ANDA211856FDA Approved
10/19/2021
TE Code
AB
On Market Since
10/20/2021
Pharmacological Classes
Price Statistics
The NADAC for CHOLESTYRAMINE PACKET has been published 238 times since Dec 22, 2021, and over the history we have for it it has declined 32.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8343 per EA |
|---|---|
| All-time high | $1.2760 (Feb 16, 2022) |
| All-time low | $0.5806 (Apr 17, 2024) |
| 52-week high | $0.9390 |
| 52-week low | $0.6721 |
| Median price | $0.8743 |
| Average price | $0.8841 |
| Largest weekly change | +34.2% (Jun 19, 2024) |
| Weeks tracked | 238 |
| Tracking since | Dec 22, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the cholestyramine powder for suspension market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ascend Laboratories, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
cholestyramine powder for suspension market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Bile Acid Sequestrant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CHOLESTYRAMINE PACKET?
The current National Average Drug Acquisition Cost (NADAC) for CHOLESTYRAMINE PACKET, manufactured by Ascend Laboratories, LLC, is $0.8343 per EA (NDC 67877029860), effective Sep 30, 2026.
How has the price of CHOLESTYRAMINE PACKET changed over time?
Over the history we have for it, the NADAC for CHOLESTYRAMINE PACKET has declined 32.4%. It has been tracked across 238 weekly CMS publications since Dec 22, 2021.
What are the highest and lowest recorded NADAC prices for CHOLESTYRAMINE PACKET?
Since Dec 22, 2021, the NADAC for CHOLESTYRAMINE PACKET has ranged from a low of $0.5806 (Apr 17, 2024) to a high of $1.2760 (Feb 16, 2022), with a median of $0.8743 per EA.
Are there cheaper alternatives to CHOLESTYRAMINE PACKET?
No other NADAC-published product currently shares the active ingredient and strength of CHOLESTYRAMINE PACKET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CHOLESTYRAMINE PACKET?
CHOLESTYRAMINE PACKET (NDC 67877029860) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.